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People are continuously exposed to radia-
tion emitted by the natural and man-made
sources. Exposures to ionizing and to non-
ionizing radiation are known to impact
human health. Effects exerted by any type
of radiation might be potentiated by co-
exposures to other types of radiation as
well as by co-exposures to chemicals and
other environmental pollutants. Inherent
individual sensitivity of persons, governed
by genetics and epigenetics, plays a role in
development of pathological processes.
In the mind of a layperson, radiation,
whether ionizing or non-ionizing, carries
often a stigma of a “danger,” and can-
cer is the dominating fatal health outcome
in the laypersons’ consideration. This is
not always the correct conclusion. Layper-
son does not always consider the radiation
dose that is of paramount importance for
the induction of radiation-related health
effects and for assessing and assigning any
health risk significance. The mere pres-
ence of radiation in the environment is
not always sufficient to be considered as
dangerous for health.
Radiation exposures are known to
induce cancer and genomic instability [for
review see (1, 2)]. Besides the role in car-
cinogenicity, radiation has also an impact
on the physiology unrelated to cancer, e.g.,
radiation-induced atherosclerosis and car-
diovascular damage (3, 4) or the induction
of cataracts (5).
Scientific knowledge should always be
the primary basis of any health and risk
communication policies. When evaluating
the scientific evidence we need not only to
determine what we know but also what we
do not know, what important topics were
not yet studied and what are the gaps in
the scientific knowledge. Only by combin-
ing the information on what we know and
presenting it in the context of what we do
not know, we can reliably evaluate the ade-
quacy of the current scientific basis of the
health protecting measures and policies.
In radiation protection, as with any
environmental factor, whether naturally
occurring or man-made, several types of
scientific evidence are needed in order to
determine human health risks:
• the possible mechanism how the effect is
induced in living organism,
• in vitro laboratory studies confirming the
existence of biophysical and biochemical
mechanisms of the effect,
• animal studies determining the effects of
exposures to very high doses of the exam-
ined factor as well as life-time exposures
to doses resembling the levels of human
exposures,
• human volunteer studies, whenever eth-
ically permissible, determining whether
the effects observed in vitro and in animal
studies occur in humans and whether the
extent of the effects is sufficient to alter
normal human physiology,
• epidemiological evidence of the impact
of radiation exposures on the health of
human population.
Each type of the evidence has differ-
ent significance and value for the estima-
tion and proving human health effect and,
consequently, in defining health policies.
Epidemiological evidence is often consid-
ered as the most important, followed by
the human volunteer studies and animal
experiments. In vitro evidence does not
directly inform about the possible health
impact in humans, but it provides infor-
mation on the possible mechanism of the
effect. Knowing the mechanism of the
effect increases the reliability of the evi-
dence gathered in epidemiological, human
volunteer, and animal studies. In the ideal
situation, all above-listed types of scientific
evidence will point into the same direction.
Epidemiological studies are often
expected to provide the ultimate answer
whether radiation exposure is hazardous
to humans. However, discovering and
validation of any potential health haz-
ard using epidemiological approach is
seriously hampered by the low sensitiv-
ity of the epidemiological methodology.
The low sensitivity of the epidemiological
approach means that it can detect strong
manifestations of health effects in human
population but it is often insufficient and
inadequate to reliably detect the health
impact of the weak biological effects that
might be induced by the low doses of
radiation. To prove the causality link of
rare effects or rare diseases, epidemiologi-
cal approach requires establishing of very
large cohorts, which is both difficult to
achieve in practice and very costly (6, 7).
Hence, epidemiological evidence is often
too ambiguous to be reliably interpreted
and used in the development of health pol-
icy. These are the circumstances where the
non-epidemiological scientific evidence
becomes of paramount importance for
policy makers.
Current science is clear on the health
risks of the acute exposures to high doses
of ionizing or non-ionizing radiation.
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However, knowledge of the: (i) delayed
effects of radiation exposure, (ii) effects
of the chronic exposures to radiation and,
especially, (iii) the effects of the exposures
to low-dose radiation, is insufficient to
reliably guide health policy.
The borderline between high, moder-
ate, and low doses of radiation is not a
rigid one and varies somewhat between
studies and research groups. Based on
measurements of cell damage or death
using human lymphocytes, low doses of
ionizing radiation have been judged to
be 20–40 mSv. Data from epidemiologi-
cal studies suggest a value of 200 mSv
for the upper limit for low-dose expo-
sure. Based on animal studies on induction
of solid tumors and leukemia, a value of
0.1 Gy/min has been suggested as a low
dose-rate regardless of the total dose (8).
Recently, values of 100 mSv (9) and 0.5 Gy
(10) have been considered as low doses.
For UV radiation (180–400 nm), the low
doses are considered to be the doses (per
square meter) below the exposure limit of
30 J/m2 (effective spectrally weighted) set
by the International Commission on Non-
Ionizing Radiation Protection (ICNIRP)
(11). For radio-frequency electromag-
netic fields (RF-EMF) of the low val-
ues may be considered to be the values
below the absorbed “dose-rate” per kilo-
gram of 2 W/kg (for 100 kHz–10 GHz) as
specified by the present ICNIRP Guide-
lines (12).
Some examples of the ongoing scientific
controversies about radiation-involvement
in the induction of human health effects
are, e.g., delayed non-cancer effects of
high doses of ionizing radiation (13, 14),
bystander effects of low-dose ionizing radi-
ation (15), children leukemia in the vicin-
ity of nuclear power plants (9) or elec-
tric power lines (16), and health effects
of wireless communication devices (17–
19). Later on these scientific controver-
sies make it difficult to reliably determine
human health risk and to set reliable health
policies.
Elucidation and prediction of all possi-
ble biological and health-related effects of
radiation are currently hampered by the
insufficient knowledge of the molecular-
level effects. The low-dose effects are small
and, therefore, difficult to discover and
assess their impact on normal human phys-
iology. The limiting factor is the lack of the
knowledge of the molecular targets absorb-
ing radiation and the mechanisms of trig-
gering the molecular chain of events lead-
ing to observed biological effects. The acute
biological effects of the high doses of radi-
ation are known. However, predicting the
delayed responses – occurring often many
years after the initial exposure – is diffi-
cult because of the lack of the knowledge
of the diversity of the molecular signaling
pathways activated by the initial exposure.
The comprehensive discovery of the
molecular targets and signaling pathways
activated by the radiation exposures is
now within the reach. The modern high-
throughput screening techniques (HTSTs)
allow global evaluation of the changes in
cellular genome, transcriptome, proteome,
and metabolome. The use of the HTSTs
in studying biological effects of radiation
exposures will reveal biological effects not
possible to predict on the basis of the
currently available knowledge (20).
High-throughput screening techniques
are already widely used in clinical research
in the search of biomarkers of diseases (21–
26) and in environmental toxicology (27–
30). Further on, their use has been shown
to provide new insights into the biological
mechanisms of, e.g., aerial pollutant – ben-
zene (31) and water pollutant – arsenic
(32); re-examining the presently known
effects of radiation by using the HTST will
lead to a broader and more comprehensive
picture of the radiation effects.
With the help of HTSTs, a large amount
of information on the global changes in
physiology of living organisms can be
obtained rapidly and efficiently, when com-
pared with more traditional non-HTST
approaches. Combining the information
obtained with HTST on the responses
of human genome, transcriptome, pro-
teome, and metabolome allow gaining new
insights into the normal and pathologi-
cal physiology of cells, tissues, and organ-
isms. At this point, because the HTST-
analyses of the vast numbers of genes,
transcripts, proteins, and metabolites may
produce variety of false positive discover-
ies (33, 34), screening with HTSTs has to
be considered as just the beginning of the
discovery process. Therefore, the validity
of the changes detected by using HTST
and hypotheses built on these discoveries
need to be confirmed by other, non-HTST
methods.
Research of biological and health effects
of radiation is still waiting for the “infor-
mation boom” already delivered in other
research areas by the use of HTSTs. Search
through the scientific literature shows only
a very limited number of studies using
HTSTs in examining the effects of radia-
tion, as seen in the recent review of the
studies using systems biology approach
(35) and proteomics methods (36–38).
Introduction of any regulatory mea-
sures needs to be rooted in the science,
and any changes should stem from the
new scientific information. “Radiation and
Health,” a specialty of “Frontiers in Public
Health,” is aimed at the scientific commu-
nity and at the decision makers interested
in health effects caused by exposures to
radiation. The aim of “Frontiers in Pub-
lic Health – Radiation and Health” is to
provide a comprehensive overview of the
science that form the basis for health policy
decisions and used to develop new health
policies. This task will be achieved through
publication of scientific studies from the
diverse research areas examining:
• policies to mitigate radiation-related
health risks,
• risk estimation of radiation exposures of
individuals as well as of human popula-
tion as a whole,
• new, science-based, approaches of risk
communication about the dangers of
radiation exposures that will emphasize
reliable and open information to avoid
triggering of unfounded scare,
• the impact caused by radiation exposure
on both physiological and psychological
aspects of human health examined by
epidemiological approach in population,
• effects of radiation exposures on human
physiology by biomedical approaches,
• animal radiation toxicology studies pri-
marily designed to assist in estimation of
human health risk caused by acute and
chronic radiation exposures,
• in vitro laboratory studies examining
biophysical and biochemical mecha-
nisms of the physiological effects of radi-
ation exposures (in vivo and ex vivo) on
human tissues and cells,
• “omics” studies that examine globally
effects of radiation on humans and ani-
mals using high-throughput methods of
genomics, transcriptomics, proteomics,
and metabolomics; the “omics” approach
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will help to comprehensively discover sig-
naling pathways and molecules targeted
by radiation exposures and to develop
new and more precise hypotheses about
known as well as yet undiscovered phys-
iological effects of radiation.
The Grand Challenge for “Frontiers in
Public Health – Radiation and Health”
is to broadly report on the implemen-
tation of the modern research methods
of genomics, transcriptomics, proteomics,
and metabolomics to study effects of radi-
ation exposures on living matter. The com-
prehensive knowledge of the diverse mol-
ecular basis of the origin of the biological
effects will help to develop better ways and
means for predicting all potentially possi-
ble detrimental effects of radiation expo-
sures, both the cancer-related and non-
cancer outcomes. The Grand Challenge for
future radiation research is to provide new
molecular-level scientific information, by
examining new research areas and revis-
iting the old ones. This global informa-
tion will be then available for the public
policy makers, allowing them to develop
new and better, firmly science-based health
protecting policies.
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